OraSure Technologies (NASDAQ:OSUR) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

OraSure Technologies (NASDAQ:OSUR) announced its earnings results on Wednesday. The medical instruments supplier reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.07, FiscalAI reports. The company had revenue of $30.64 million for the quarter, compared to the consensus estimate of $29.10 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Q2 revenue exceeded guidance: Total revenue was $30.6 million, up 9.7% sequentially, led by stronger diagnostics demand and 9% sequential growth in Sample Management Solutions. GAAP gross margin improved 120 basis points sequentially to 43.5%.
• OraSure received FDA clearance for its Colli-Pee Dx urine collection kit for eight STI testing indications and FDA Emergency Use Authorization for its second-generation OraQuick Ebola rapid antigen test, creating potential launch-related growth opportunities.
• IntelliQuick CT/NG timing slipped: The company withdrew its FDA submission after agency discussions and no longer expects U.S. clearance or launch in 2026, although management plans to resubmit and maintained its 2026 growth outlook.
• International diagnostics initiatives are expanding, including localized HIV self-test supply programs and Sickle SCAN, whose 2026 revenue is growing twice as fast as in 2025. Sample Management Solutions is also seeing recovery across advanced genetic testing laboratories, microbiome collection, and research channels.
• The company ended the quarter with $161 million in cash and no debt, while operating cash flow was negative $9.9 million; management expects operating cash flow to reach break-even as it enters 2027. Q3 revenue guidance is $29.5 million to $32.5 million, with gross margin expected to remain near Q2 levels.

OraSure Technologies Price Performance

OSUR stock traded down $0.02 during midday trading on Wednesday, reaching $4.15. The company had a trading volume of 239,307 shares, compared to its average volume of 346,892. The company has a market capitalization of $285.73 million, a P/E ratio of -3.99 and a beta of 1.00. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.58. The firm has a 50-day moving average price of $4.17 and a 200-day moving average price of $3.41.

Insider Buying and Selling at OraSure Technologies

In related news, Director Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock in a transaction on Thursday, May 14th. The shares were acquired at an average cost of $2.99 per share, with a total value of $74,750.00. Following the transaction, the director owned 113,462 shares in the company, valued at $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On OraSure Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its stake in OraSure Technologies by 57.8% in the 4th quarter. XTX Topco Ltd now owns 121,144 shares of the medical instruments supplier’s stock worth $293,000 after purchasing an additional 44,379 shares during the period. Hsbc Holdings PLC grew its holdings in shares of OraSure Technologies by 96.3% in the fourth quarter. Hsbc Holdings PLC now owns 135,091 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 66,260 shares during the last quarter. Invesco Ltd. raised its position in OraSure Technologies by 11.1% during the 4th quarter. Invesco Ltd. now owns 161,182 shares of the medical instruments supplier’s stock valued at $390,000 after purchasing an additional 16,041 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of OraSure Technologies by 50.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 183,285 shares of the medical instruments supplier’s stock valued at $444,000 after purchasing an additional 61,300 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of OraSure Technologies by 14.1% during the 2nd quarter. Jane Street Group LLC now owns 157,871 shares of the medical instruments supplier’s stock worth $474,000 after purchasing an additional 19,494 shares during the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OSUR has been the subject of several research analyst reports. Weiss Ratings upgraded shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Wall Street Zen downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Sunday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.